Exact Sciences Corp nhasi yakazivisa kuti data kubva kuRx yePositive Node, Endocrine Responsive Breast Cancer, kana RxPONDER, muyedzo wakaburitswa muThe New England Journal of Medicine.i Chidzidzo ichi, chinotungamirwa neyakazvimiririra SWOG Cancer Research Network uye yakatsigirwa neThe New England Journal of Medicine. National Cancer Institute (NCI), yakabudirira kutsanangura kubatsirwa kwechemotherapy mukutanga-nhanho, node-positive kenza yemazamu varwere vane Oncotype DX Breast Recurrence Score® mhedzisiro ye0 kusvika 25. Mhedzisiro yekutanga kubva kuRxPONDER yakashumwa pa2020 San Antonio Breast Cancer. Symposium (SABCS). Izvo zvakawanikwa zvino zvakasimbiswa mune ino yakaongororwa nevezera bhuku.
Zvakakosha, hapana chemotherapy inobatsira yakaonekwa zvisinei nehuwandu hweakakanganisika node, bundu giredhi kana saizi. Muvakadzi vasati vasvika kumwedzi vane 1 kusvika ku3 yakanaka nodes, nhamba inokosha yechemotherapy inobatsira yakaonekwa.
Anenge chikamu chimwe muzvitatu chevarwere vakaonekwa vaine mahormone receptor (HR) -positive, HER2-negative kenza yemazamu yekutanga vane bundu ratopararira kumalymph nodes avo. Ruzhinji rwevarwere ava parizvino vanowana chemotherapyii kunyangwe 85% yavo vaine Recurrence Score mhedzisiro ye0 kusvika 25.iii Pamusoro pezvo, vangangosvika vaviri kubva kune vatatu varwere vegomarara rezamu rekutanga vari postmenopausal.iv
Zvichienderana nemhedzisiro yeRxPONDER, iyo National Comprehensive Cancer Network® (NCCN®)v yakagadziridza gwara rayo regomarara rezamu uye yakaziva Oncotype DX Breast Recurrence Score bvunzo seye chete bvunzo inogona kushandiswa kufanotaura kubatsirwa kwechemotherapy mukutanga-danho rezamu. varwere vegomarara vane 1 kusvika 3 positive axillary lymph nodes, kusanganisira micrometastases.vi The Oncotype DX bvunzo ndiyo chete bvunzo inonzi "inodiwa" nehupamhi hwepamusoro hwehumbowo hwenode-negative uye postmenopausal node-positive (1 kusvika 3 positive node ) varwere. Pamusoro pezvo, NCCN inokurudzira kutarisisa bvunzo yekuongorora kufungidzira mune premenopausal node-positive varwere vari kukwikwidza chemotherapy.
Imwe yemakiriniki makuru miedzo mu node-positive, HR-positive, HER2-negative kenza yemazamu yekutanga, RxPONDER yakanyoresa vakadzi vanopfuura zviuru zvishanu vane mafundo anosvika matatu akanaka. Chidzidzo chinotarisirwa, chechikamu chechitatu chakaitwa panzvimbo dze5,000 munyika pfumbamwe - United States, Canada, Mexico, Colombia, Ireland, France, Spain, South Korea neSaudi Arabia. Vakadzi vane Recurrence Score mhedzisiro ye632 kusvika 0 vakangoitwa kuti varapwe nehormone therapy chete kana chemotherapy inoteverwa nehomoni therapy. Varwere vasina kurongeka vakaiswa stratified zvichibva pane yavo Recurrence Score mhedzisiro, menopausal mamiriro uye mhando yekuvhiya lymph node. Kumwe kuongorora uye kumwe kuteedzera murwere kunorongwa nevanoongorora SWOG.
ZVOKUBVA MUNYAYA INO:
- Based on the RxPONDER results, the National Comprehensive Cancer Network® (NCCN®)v updated its guidelines for breast cancer and recognized the Oncotype DX Breast Recurrence Score test as the only test that can be used for prediction of chemotherapy benefit in early-stage breast cancer patients with 1 to 3 positive axillary lymph nodes, including micrometastases.
- I The study, led by the independent SWOG Cancer Research Network and sponsored by the National Cancer Institute (NCI), successfully defined the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Oncotype DX Breast Recurrence Score® results of 0 to 25.
- Women with a Recurrence Score result of 0 to 25 were randomized to treatment with hormone therapy alone or chemotherapy followed by hormone therapy.
